Press

1. IntelliDose Launches IntelliScribe March 2, 2010
2. IntrinsiQ Sharpens Cancer Treatment Analysis February 10, 2010
3. Dayton Physicians Commits to Clinical Excellence by Partnering with IntelliDose February 2, 2010
4. IntelliDose Exhibiting at Fifth Annual Community Oncology Conference February 5–6, 2010
5. New York cancer care center uses automation to handle coding, reimbursement January 29, 2010
6. Tarceva Reprieve? FDA Delay Could Mean Little Either Way January 25, 2010
7. WWMR Vice President Invited to Speak at PBIRG Fall Biotech Workshop December 7, 2009
8. Panel Advises on Clinical Pathways: What, Why, and How November, 2009
9. IntrinsiQ Expands Executive Team November 3, 2009
10. IntelliDose Exhibiting at North Carolina Oncology Management Society 2009 Fall Conference November 18 to 20, 2009
11. Opportunity reconsidered: maintenance therapy in oncology October, 2009
12. IntrinsiQ Study: Oncologists Overlook Maintenance Therapy Option – More Often than They Realize September 15, 2009
13. Industry Thought Leaders: A Discussion with Jeff Forringer, President of IntrinsiQ, LLC August 2009
14. Are CPOEs worth the investment? August 2009
15. Information Technology: Tracking the Evolution of Oncology Drug Prescribing August 2009
16. Rich Gray, General Manager of IntelliDose, to Speak at ACCC 26th National Oncology Economics Conference September 22 to 25, 2009
17. IntelliDose Exhibiting at eClinicalWorks 2009 National Users Conference September 12 to 15, 2009
18. Jeff Forringer, President of IntrinsiQ, to Speak at the Magellan/ICORE 6th Annual Oncology Summit September 11, 2009
19. IntelliDose Exhibiting at GE Centricity User Group Fall Conference August 28 and 29, 2009
20. How Much Should Cancer Drugs Cost: Landmark Cornell University Study Sheds New Light on Old Assumptions August 4, 2009
21. IntrinsiQ Sponsors Cancer Center Business Summit October 8-9, 2009
22. The First Step to a Paperless Practice July 1, 2009
23. On the Move – Spotlight on Jeff Forringer June 19, 2009
24. Specialized chemotherapies increase market share, cost of care June 2009
25. IntrinsiQ Acquires Market Research Firm WWMR June 9, 2009
26. IntrinsiQ Appoints New Executive Team May 12, 2009
27. IntrinsiQ's IntelliDose May 2009
28. The real cost of treating off-label and off-guidelines March 2009
29. NewsMakers March 2009
30. Small mistakes, huge consequences; Onc-specific software improves safety February 2009
31. Safe Handling; The Right Drug, Right Dose, Right Patient January/February 2009
32. Automated Oncology February 2009
33. Still Using Paper and Pen? January 2009
34. OnCare Hawaii Selects IntelliDose for Oncology Patient Safety and Practice Efficiency January 6, 2009
35. Safe Handling December 2008
36. Market Opportunity in Lung Cancer December 2008
37. Cancer Center of South Florida Selects IntelliDose for All-Electronic Practice November 3, 2008
38. IntrinsiQ Launches IntelliDose 3.8 October 27, 2008
39. Technology: Can Oncology EMRs Improve Quality? September 2008
40. IntrinsiQ Builds Out Its Oncology-Products Market Analytics September 2008
41. IntrinsiQ Wins 3 Top Honors from Inc. Magazine September 9, 2008
42. New Reporting from IntrinsiQ Measures Impact of Key Events on Oncology Drug Usage September 2, 2008
43. High Drug Costs a Factor in Cancer Care August 28, 2008
44. Pharmawire analysis: Cyclacel's seliciclib comes under physician scrutiny August 2008
45. DSS Licenses IntelliDose to Standardize VA Oncology Practices August 18, 2008
46. Buried Treasure June 23, 2008
47. Data from the Doctor April 15, 2008
48. IntrinsiQ LLC - Dose of Success March 7, 2008
49. IntelliCost Provides Cost of Therapy Insight for Sizing New Market Opportunities February 13, 2008
50. Software application aims to eliminate human error in chemotherapy dosing January 11, 2008
51. Oncologists Nationwide Choose IntelliDose for Clinical Safety and Efficiency November 28, 2007
52. IntrinsiQ Expands Oncology’s Gold-Standard for Patient Data Collection September 25, 2007
53. IntelliDose to Participate in ASCO EHR Symposium July 19, 2007
54. GE Healthcare and IntrinsiQ Announce Collaboration to Link Clinical Oncology Information within Patient Electronic Medical Records May 31, 2007
55. IntelliDose® Unveils IntelliCharge — Automated Encounter Charge Capture Improves Control and Billing of Costly Chemotherapy Drugs May 31, 2007
56. PRA International and IntrinsiQ Research Enter Exclusive Agreement for Oncology Patient Treatment Data March 19, 2007
57. Pulse and IntrinsiQ Sign Strategic Agreement January 16, 2007
58. IMS, IntrinsiQ Research Establish Strategic Alliance to Deliver Global, Clinically Rich Oncology Market Intelligence August 2, 2006
59. Accel-KKR Acquires Majority Stake in IntrinsiQ June 20, 2006

New Reporting from IntrinsiQ Measures Impact of Key Events on Oncology Drug Usage

Event IntelliView Quantifies and Tracks Market Responses to FDA Approval, Pricing Changes and Clinical Trial Results

WALTHAM, Mass. (Sept. 2, 2008) — IntrinsiQ, LLC, the expert source for clinical oncology insight, today launched Event IntelliView, a new analysis tool that quantifies the real-world impact of key events in the lifecycle of medical oncology drugs.

Pharmaceutical research teams can now quickly make sense of vast amounts of product performance data, and see how activities like reporting on clinical findings, regulatory approvals and price changes positively or negatively impact market penetration. This insight gives crucial corporate understanding of what ultimately drives the usage of oncology products and competitive threats that might impact future growth rates.

Event IntelliView standardizes publicly available information on major market activities and ties them directly to IntrinsiQ’s real-time, real-world performance data of oncology drug therapies, easily searchable by product and event. This high-level of visibility enables pharmaceutical companies to more accurately predict growth and anticipate potential threats based on how oncologists respond to factors like:

• Dramatic price increases which significantly hindered Velcade’s market performance

• A negative FDA opinion for use of Avastin in breast cancer brought negative pressure prior to the ultimate, unexpected regulatory approval

• The wide spectrum of available clinical data drove two distinct inflection points of uptake of Oxaliplatin in colorectal cancer

“Pharmaceutical research teams are under increasing pressure to explain why a drug fared one way or another and how a drug’s lifecycle and profit window can be extended,” said Brent Clough, IntrinsiQ’s CEO. “They now have the ability to show what’s at stake and make sound recommendations based on unimpeachable market data.”

Available now, Event IntelliView’s reporting is updated quarterly.

About IntrinsiQ

IntrinsiQ, LLC is the leading provider of medical oncology workflow solutions and the premier source of US oncology data and analysis. Each month, IntrinsiQ’s market leading software application, IntelliDose®, captures the treatment decisions and details from more than 500 oncologists, for more than 19,500 unique patients, and regarding more than 128,000 drug administrations. The IntrinsiQ database is unrivaled in accuracy, detail and timeliness of information about the medical oncology care process. This database is the foundation of products and services that uniquely address the business information needs of pharmaceutical product managers, market researchers and financial analysts. For more information, please visit www.intrinsiq.com.

IntrinsiQ Company Contact:

Ted Owens
(781) 434-3331
ted.owens@intrinsiq.com

IntrinsiQ Media Contact:

Lesley Cannata
(617) 969-9192
lcannata@corporateink.com

© 2010 IntrinsiQ, LLC